ODI Medical is a Norwegian start-up company that has invented the Oxygen Delivery Index (ODIN), a “physiological biomarker” that allows to precisely quantify O2 delivery. Thanks to the support from both institutional (e.g. The Research Council of Norway or Innovation Norway) and corporate (e.g. Novo Nordisk Foundation) funding bodies, we have been able to develop OXIMONITOR, the first-ever medical device accurately measuring the microcirculatory function. Our technology is based on 30 years of research conducted by Professor Knut Kvernebo (MD, PhD) from Oslo University Hospital. ODI Medical's solution is the OXIMONITOR which is a bedside, accurate and cost-effective fully integrated platform incorporating 2 main components: (1) The mLab is a non-invasive point of care (POC) device that uses computer assisted video microscopy and diffuse reflectance spectroscopy to create an “optical fingerprint” of the patient’s circulatory function. Data is collected from the surface of the patient’s skin, but could also be collected from the conjunctiva or sublingually. (2) The cLab component is a cloud computing system based on machine learning technology that collects and, analyses the data and generates the patient´s interpretation report. This report is then sent back to the clinical site through a user-friendly dashboard for decision-making. The prognostic value from OXIMONITOR has been confirmed in a proof-of-concept clinical trial with ECMO patients and a follow-up multi-center clinical trial including over 60 patients (interim data). Our goal is to complete the development of the platform and start commercializing it in hospitals and other healthcare institutions to treat ECMO patients as a 1 st clinical application by 2021. Our technology is at TRL6 (figure 6), having a working prototype where cLab and mLab are integrated. We successfully tested our prototype at OUH (Oslo University Hospital) in a proof-of-concept clinical trial.
Project leader: Alison Sundset
Institution: ODI MEDICAL AS